Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
9,823
Total Claims
$4.9M
Drug Cost
1,019
Beneficiaries
$4,798
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 13,194 Neurology providers
+94%
Opioid rate vs peers
2.5% vs 1.3% avg
+19%
Cost per patient vs peers
$4,798 vs $4,034 avg
+23%
Brand preference vs peers
11.6% vs 9.4% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
2.5%
Opioid Rate
249
Opioid Claims
$6,616
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 1,130 claims · $4.1M
Generic: 8,596 claims · $789K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Teriflunomide | 67 | $694K |
| Deutetrabenazine | 52 | $570K |
| Dimethyl Fumarate | 40 | $392K |
| Fingolimod Hcl | 26 | $298K |
| Ofatumumab | 29 | $292K |
| Glatiramer Acetate | 31 | $187K |
| Dimethyl Fumarate | 97 | $151K |
| Lacosamide | 52 | $123K |
| Interferon Beta-1a | 13 | $119K |
| Levetiracetam | 38 | $119K |
| Interferon Beta-1a | 13 | $110K |
| Interferon Beta-1b | 11 | $108K |
| Eslicarbazepine Acetate | 42 | $89K |
| Rimegepant Sulfate | 44 | $86K |
| Galcanezumab-Gnlm | 80 | $70K |
Prescribing Profile
100
Unique Drugs
24.0
Anomaly Score
Patient Profile
67
Avg Age
58%
Female
1.48
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About